Read Entire DisclaimerBona, Bona Film Group Limited, Crown Equity Holdings, CRWE, CRWE Ad Services, Nasdaq:BONA, Nasdaq:SGNT, NYSE:PLX, PLX, Protalix BioTherapeutics, Sagent Pharmaceuticals, SGNT
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) reported the launch of Oxaliplatin for Injection, USP, the generic form of the chemotherapy drug, Eloxatin(r), in two latex-free vial presentations.
According to IMS data for the twelve-months ended June 2012, the U.S. market for Oxaliplatin for Injection, USP approximated $1.7 billion. As with all products in Sagent’s portfolio, Oxaliplatin features the company’s PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
Bona Film Group Limited (Nasdaq:BONA), a leading film distributor and vertically integrated film company in China, reported that the Company will report its unaudited financial results for Second quarter ended June 30, 2012, on Thursday, August 23, 2012 after market close.
CRWE AD-Services, a division of CRWE is a full service multimedia advertising company specializing in internet marketing. Their goal is to provide you with a customized advertising blue print using their expansive resources. CRWE Ad Services (www.crwe-adservices.com ) provides modern and unique advertising campaigns. They are dedicated to offering the most cost effective advertising solutions.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWE advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com.
Protalix BioTherapeutics, Inc. (NYSE:PLX) reported that Yossi Maimon, the Company’s Chief Financial Officer, will present at the Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012 at 8:30 AM ET at the InterContinental Hotel in Boston, MA.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE) advertises for a particular client, Crown Equity Holdings Inc. (CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE), if paid in stock, can and may sell those securities during the advertising period.